Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

122 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-24

Study Completion Date

2021-09-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bacille Calmette-Guerin (BCG) is a live attenuated vaccine administered for prevention of tuberculosis. Recently, several groups have hypothesized that BCG may "train" the immune system to respond to a variety of unrelated infections, including viruses and in particular the coronavirus responsible for COVID-19. Trials are currently being conducted in Australia, Netherlands, Germany and the United Kingdom to evaluate its effectiveness.

Front line workers includes members of municipal and provincial police services, emergency medical personnel, firefighters, public transport employees, health service workers and food manufacturing employees. They are at high risk of infection from COVID-19, with potentially high infection rate. The investigators propose an interventional trial to evaluate the effectiveness of BCG vaccination to prevent COVID-19 infection and reduce its severity in front-line employees in Ontario.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

NCT04387409

Infection, Respiratory Tract

UNKNOWN PHASE3

Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

NCT04435379

Infection, Respiratory Tract

COMPLETED PHASE3

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers

NCT00749034

Tuberculosis Healthy

COMPLETED PHASE1

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

NCT03349983

Safety Issues

COMPLETED PHASE1

Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers

NCT06975319

Healthy Immunisation Against Streptococcus Pneumoniae

ACTIVE_NOT_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

The clinical trial is designed as a double-blind (observer blind) study. Observer-blind means that during the course of trial, the companions/parents/guardians of the subjects and the study personnel responsible for the evaluation of any study endpoint will be unaware which vaccine was administered.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VPM1002

A single dose of 0.1 mL of the reconstituted vaccine containing VPM1002 (Mycobacterium bovis rBCGΔureC::hly, live 2-8 × 105 CFU), administered via intradermal injection.

Group Type EXPERIMENTAL

VPM1002

Intervention Type BIOLOGICAL

VPM1002 is a recombinant BCG (rBCG)

Placebo

A single dose of 0.1 mL of the 0.9% sodium chloride injection, administered via intradermal injection.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

0.9% sodium chloride

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VPM1002

VPM1002 is a recombinant BCG (rBCG)

Intervention Type BIOLOGICAL

Placebo

0.9% sodium chloride

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Mycobacterium bovis rBCGΔureC::hly sodium chloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eighteen years of age or older
* Employee/member of: municipal or provincial police service, emergency medical services, fire services, public transport service, health service, food manufacturing facility

Exclusion Criteria

* Prior intravesical BCG or intradermal BCG, with the exception of tuberculosis vaccination in childhood.
* Previous known history of latent or active tuberculosis
* Known kidney, liver or blood disorders which impairs organ and marrow function
* Chronic administration of steroids (\>10 mg prednisone) at the time of randomization
* Current or planned concomitant biologic therapy in the next 7 months.
* Known hypersensitivity or allergy to components of VPM1002
* Pregnant or planning to become pregnant in the future 7 months.
* Breastfeeding.
* Current suspected viral or bacterial infection.
* Body temperature \> 38° C
* Participation in another interventional study with potentially conflicting medication within 30 days before screening.
* The presence of an impaired immune response irrespective of whether this impairment is congenital or caused by disease, drugs or other therapy (e.g., anti-TNF therapy, methotrexate, azathioprine, antimalarials).
* Active malignancy requiring treatment.
* Known positive HIV serology.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG vaccine.
* Previous positive COVID-19 confirmed infection.
* Uncontrolled intercurrent illness.
* Psychiatric illness/social situations that would limit compliance with study requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes